| abstract |
(I) as a therapeutic agent for a cholinergic characteristic-related disorder, a smooth muscle contraction-related disorder, an endocrine disorder, a neurodegenerative disease, etc. of the central nervous system (CNS) and / or the peripheral nervous system (PNS) [In the above equation A is CR 1E or a nitrogen atom, XYZ is the like N-CO-NR 3A R 3B , R 1A to R 1E is the like the hydrogen atoms independently, R 2A through R 2D has the like, independently, a hydrogen atom, R 3A and R 3B Are each independently optionally substituted C 3-10 cycloalkyl and the like, n is 1 or 2.] Or a pharmaceutically acceptable salt thereof, Indicating potential regulatory effects on the nicotinic acetylcholine receptor ([alpha] 7 nAChR) activity. |